<DOC>
	<DOCNO>NCT02401191</DOCNO>
	<brief_summary>Primary Objective : To assess safety twice-daily fexofenadine 60 mg/phenylephrine 10 mg ( FEX60/PE10 ) combination tablet patient allergic rhinitis . Secondary Objective : To evaluate effectiveness twice-daily FEX60/PE10 combination tablet nasal symptom ( sneeze , rhinorrhea , nasal congestion ) , daily activity impairment .</brief_summary>
	<brief_title>A Study Assessing Safety Effectiveness FEX60/PE10 Fixed Combination Tablet Patients With Allergic Rhinitis</brief_title>
	<detailed_description>It 22 day minimum 32 day depend screening , treatment , post-treatment observation allowance .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Inclusion criterion : Outpatients history seasonal perennial allergic rhinitis least 1 year confirm positive skin prick test indoor allergen ( wheal â‰¥3mm compare control [ diluent ] ) positive specific IgE Antibody test ( ie , radioallergosorbent test [ RAST ] , etc . ) day provisional inclusion trial . Patients meet follow criterion symptom score . ( The symptom score rat accord 'Severity nasal symptom ' ) : 1 . Nasal congestion score consistently 2 3 4 last 3 day screen period . 2 . Score sneeze rhinorrhea consistently 2 3 4 throughout last 3 day screen period . Patients age 15 year old , restriction gender . Patients write informed consent . Females childbearing potential must negative pregnancy test perform within 7 day prior start study drug adequate contraception study . Exclusion criterion : Patients nasal disease ( hypertrophic rhinitis , paranasal sinusitis , nasal polyp , acute rhinitis , deviation nasal septum , etc . ) could interfere judgment efficacy investigational product ( IP ) patient develop coldlike symptom screen period . Patients severe asthma , bronchiectasis , severe hepatic , renal , cardiac dysfunction , hematological , endocrine disease , serious complication . Patients unstable medical condition like diabetes mellitus , heart failure , hepatic renal impairment . Patients history epilepsy organic brain disease , may cause epilepsy . Patients take follow medication may affect evaluation IP , Patients use intranasal systemic decongestant stop 3 day inclusion visit . 1 . Within 1 week prior day registration : Intranasal oral : Antiallergic drug , antihistamine , anticholinergic agent , vasoconstrictor , antihistaminecontaining cold remedy , agent expect antiallergic/antihistaminic effect ( include Chinese medicine glycyrrhizin ) , agent indicate allergic symptom ( sneeze , rhinorrhea , nasal congestion , etc. ) . Agents may affect blood concentration Fexofenadine ( FEX ) ( macrolide antibiotic , azole fungicide , preparation contain aluminum hydroxide/magnesium hydroxide ) . 2 . Within 2 week prior day registration : Steroids , immunosuppressant , nonspecific alternative therapy ( histaminecontaining gammaglobulin preparation etc ) . 3 . Within 4 week prior day registration : Patients receive oral , nasal , inhaled corticosteroid . Depot steroid preparation . Patients use sodium cromoglycate/nedocromil leukotriene modifier stop 14 day inclusion . Patients immunotherapy specific immunotherapy start dose change approximately 1 month precede enrolment study , ( dos maintain dose throughout trial ) . Patients suffer Upper Respiratory Tract Infection , sinusitis acute otitis medium within 30 day inclusion visit . Patients participate another study previously participate another study within previous 6 month prior day registration . Patients consider Investigator/subinvestigator unsuitable enrolment study criterion previously participate study . Patients history hypersensitivity antihistamines antiallergic agent include FEX . Patients severe hypertension severe coronary artery disease , narrow angle glaucoma , urinary retention , show sensitivity adrenergic agent ( manifestation include insomnia dizziness , weakness , tremor , arrhythmia ) . Patients receive monoamine oxidase ( MAO ) inhibitor therapy within 2 week prior day registration . Women pregnant , possibly pregnant , breastfeed . Patients underlie hepatobiliary disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>